Sorafenib (Nexavar, BAY43-9006)
DrugSorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
NCT Number: NCT00562523
The purpose of this study is to: 1.) Evaluate how your body reacts to sorafenib when taken daily (continuously) in combination with docetaxel given every 3 weeks, and to determine the safety of the two drugs together.2.) Measure your blood levels of sorafenib and docetaxel at specific times after taking the medications.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Tampa, Florida, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
Time frame: 6 weeks
Time frame: 6 weeks
Looking for future studies?
Notify MeBayer
Industry
A Phase I Dose Escalation Study With Sorafenib Administered Continuously in Combination With Docetaxel Administered Once Every Three Weeks in Patients With Advanced Solid Tumors.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00145028
Neoplasms
Angers, France
View Trial DetailsNCT02423057
Neoplasms, Solid Tumors
Bethesda, Maryland, United States
View Trial DetailsNCT04442425
Cancer, Neoplasms
Bethesda, Maryland, United States
View Trial DetailsNCT03566732
Bereavement, Neoplasms
Buenos Aires, Argentina
View Trial Details